{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:57:53Z","timestamp":1788623873618,"version":"build-2803163510"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8236120373"],"award-info":[{"award-number":["8236120373"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Inflammatory skin diseases, including atopic dermatitis, psoriasis, and chronic spontaneous urticaria, substantially impair patients\u2019 quality of life. Despite therapeutic advances, current treatments often fail to achieve durable remission, underscoring the need for more precise interventions. Mast cells (MCs), traditionally recognized for their roles in IgE-mediated allergic responses, exhibit marked functional heterogeneity that shapes their pathogenic contributions to chronic skin inflammation. Recent single-cell and spatial transcriptomic analyses have identified discrete MC subsets with distinct inflammatory signatures and tissue-specific distributions, highlighting the complexity of their regulation within disease-specific microenvironments. A key mediator of non-IgE-dependent activation is Mas-related G protein\u2013coupled receptor X2 (MRGPRX2), which engages diverse ligands and triggers receptor-biased signaling pathways, thereby promoting pathological neuroimmune interactions. Although MRGPRX2-targeted small molecules and antibodies have shown preclinical potential, major translational challenges remain, including the limitations of existing animal models and the lack of validated biomarkers. This review delineates MC heterogeneity, summarizes recent insights into MRGPRX2-mediated mechanisms, critically appraises current precision-targeted therapeutic strategies, and proposes solutions to overcome translational barriers. It is suggested that integrating advanced humanized models, longitudinal multi-omics profiling, and standardized functional assays may accelerate clinical translation and support the development of MC-targeted precision medicine.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1680574","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:15:08Z","timestamp":1760415308000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Functional heterogeneity of mast cells in cutaneous inflammation: implications for precision medicine"],"prefix":"10.3389","volume":"16","author":[{"given":"Surui","family":"A","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dugarmaa","family":"Ulzii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enkhtur","family":"Yadamsuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf071","article-title":"Global burden of skin and subcutaneous diseases: an update from the Global Burden of Disease Study","volume":"192","author":"Huai","year":"2021","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(25)00003-7","article-title":"Global, regional, and national burden of asthma and atopic dermatitis, 1990\u20132021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"13","author":"Oh","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2092352","article-title":"Impact of itch and skin pain on quality of life in adult patients with atopic dermatitis in Japan: results from a real-world, point-in-time, survey of physicians and patients","volume":"38","author":"Torisu-Itakura","year":"2022","journal-title":"Curr Med Res Opinion"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/24755303211066928","article-title":"The role of pain in the lives of patients with psoriasis: A qualitative study on an inadequately addressed symptom","volume":"7","author":"Snyder","year":"2022","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"22799036241243268","DOI":"10.1177\/22799036241243268","article-title":"Does chronic urticaria affect quality of sleep and quality of life","volume":"13","author":"Abdel-Meguid","year":"2024","journal-title":"J Public Health Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.04.003","article-title":"Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis","volume":"6","author":"Ferrer","year":"2018","journal-title":"J Allergy Clin Immunology: In Practice"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich\u2019s visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/cells10051033","article-title":"Unlocking the non-igE-mediated pseudo-allergic reaction puzzle with mas-related G-protein coupled receptor member X2 (MRGPRX2)","volume":"10","author":"Kumar","year":"2021","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1523393","article-title":"The development of murine bone marrow-derived mast cells expressing functional human MRGPRX2 for ex vivo and in vivo studies","volume":"15","author":"Bawazir","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"110984","DOI":"10.1016\/j.isci.2024.110984","article-title":"The MRGPRX2-substance P pathway regulates mast cell migration","volume":"27","author":"West","year":"2024","journal-title":"iScience"},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000487538","article-title":"The staining of mast cells: A historical overview","volume":"176","author":"Ribatti","year":"2018","journal-title":"Int Arch Allergy Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e20230570","DOI":"10.1084\/jem.20230570","article-title":"Landscape of mast cell populations across organs in mice and humans","volume":"220","author":"Tauber","year":"2023","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3390\/cells12172177","article-title":"Human mast cells upregulate cathepsin B, a novel marker of itch in psoriasis","volume":"12","author":"West","year":"2023","journal-title":"Cells"},{"key":"B14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s42003-025-07629-4","article-title":"Single cell transcriptome profiling reveals pathogenesis of bullous pemphigoid","volume":"8","author":"Liang","year":"2025","journal-title":"Commun Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20249","article-title":"Beyond the classic players: Mas-related G protein-coupled receptor member X2 role in pruritus and skin diseases","volume":"39","author":"Kumar","year":"2025","journal-title":"Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaci.2020.12.654","article-title":"PD-L1 on mast cells suppresses effector CD8+ T-cell activation in the skin in murine contact hypersensitivity","volume":"148","author":"Hirano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.immuni.2020.01.012","article-title":"Human mast cell proteome reveals unique lineage, putative functions, and structural basis for cell ablation","volume":"52","author":"Plum","year":"2020","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/cells12232700","article-title":"Synergism between IL-33 and MRGPRX2\/fc\u03f5RI is primarily due to the complementation of signaling modules, and only modestly supplemented by prolonged activation of selected kinases","volume":"12","author":"Franke","year":"2023","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616420114","article-title":"Dnmt3a restrains mast cell inflammatory responses","volume":"114","author":"Leoni","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3AB0320-547RR","article-title":"The histone deacetylase inhibitor valproic acid attenuates phospholipase C\u03b32 and IgE-mediated mast cell activation","volume":"108","author":"Rodr\u00edguez-L\u00f3pez","year":"2020","journal-title":"J Leukocyte Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02414","article-title":"Epigenetic regulation via altered histone acetylation results in suppression of mast cell function and mast cell-mediated food allergic responses","volume":"9","author":"Krajewski","year":"2018","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"111346","DOI":"10.1016\/j.celrep.2022.111346","article-title":"Mast cell regranulation requires a metabolic switch involving mTORC1 and a glucose-6-phosphate transporter","volume":"40","author":"Iskarpatyoti","year":"2022","journal-title":"Cell Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-022-00731-2","article-title":"New perspectives on the origins and heterogeneity of mast cells","volume":"23","author":"St. John","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2AB1018-405R","article-title":"Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cells","volume":"106","author":"Ogasawara","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04077-y","article-title":"Structure, function and pharmacology of human itch receptor complexes","volume":"600","author":"Yang","year":"2021","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033794","article-title":"Inhibition of MRGPRX2 but not Fc\u03f5RI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist","volume":"13","author":"Bawazir","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801227","article-title":"Angiogenic host defense peptide AG-30\/5C and bradykinin B2 receptor antagonist icatibant are G protein biased agonists for MRGPRX2 in mast cells","volume":"202","author":"Roy","year":"2019","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jid.2020.09.017","article-title":"MRGPRX2 is the codeine receptor of human skin mast cells: desensitization through \u03b2-arrestin and lack of correlation with the fc\u03f5RI pathway","volume":"141","author":"Babina","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.3390\/ijms22105318","article-title":"Substance P serves as a balanced agonist for MRGPRX2 and a single tyrosine residue is required for \u03b2-arrestin recruitment and receptor internalization","volume":"22","author":"Chompunud Na Ayudhya","year":"2021","journal-title":"IJMS"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","article-title":"Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic itch","volume":"50","author":"Meixiong","year":"2019","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.3390\/ijms24055001","article-title":"Molecular mechanisms of neurogenic inflammation of the skin","volume":"24","author":"Marek-Jozefowicz","year":"2023","journal-title":"IJMS"},{"key":"B32","doi-asserted-by":"publisher","first-page":"16146","DOI":"10.1038\/s41598-020-72819-5","article-title":"Identification of the dog orthologue of human MAS-related G protein coupled receptor X2 (MRGPRX2) essential for drug-induced pseudo-allergic reactions","volume":"2020","author":"Hamamura-Yasuno","year":"2020","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jid.2023.06.201","article-title":"Mast cells initiate type 2 inflammation through tryptase released by MRGPRX2\/MRGPRB2 activation in atopic dermatitis","volume":"144","author":"Jia","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/biomedicines13030656","article-title":"Neurogenic inflammation in allergic contact dermatitis","volume":"13","author":"Aitella","year":"2025","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.027","article-title":"Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies","volume":"147","author":"K\u00fchn","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/itx.0000000000000005","article-title":"MRGPRX2, atopic dermatitis, and red man syndrome","volume":"2","author":"Azimi","year":"2017","journal-title":"Itch"},{"key":"B37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/ph17040494","article-title":"Orally bioavailable proteolysis-targeting chimeras: an innovative approach in the golden era of discovering small-molecule cancer drugs","volume":"17","author":"Rej","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.07.002","article-title":"Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists","volume":"154","author":"Wollam","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.805","article-title":"Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction","volume":"151","author":"Kumar","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-025-02209-8","article-title":"Subnanomolar MAS-related G protein-coupled receptor-X2\/B2 antagonists with efficacy in human mast cells and disease models","volume":"10","author":"Al Hamwi","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433982","article-title":"Pharmacological blockade of the mast cell MRGPRX2 receptor supports investigation of its relevance in skin disorders","volume":"15","author":"Macphee","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"109063","DOI":"10.1016\/j.intimp.2022.109063","article-title":"Clarithromycin-treated chronic spontaneous urticaria with the negative regulation of Fc\u03f5R\u03b9 and MRGPRX2 activation via CD300f","volume":"110","author":"Che","year":"2022","journal-title":"Int Immunopharmacology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.3390\/ijms22116116","article-title":"The function of the histamine H4 receptor in inflammatory and inflammation-associated diseases of the gut","volume":"22","author":"Schirmer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12726","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ -39758979) in J apanese adults with moderate atopic dermatitis","volume":"42","author":"Murata","year":"2015","journal-title":"J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","article-title":"Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis","volume":"143","author":"Werfel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70032","article-title":"Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study","volume":"17","author":"Jin","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae038","article-title":"Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial","volume":"190","author":"Grekowitz","year":"2024","journal-title":"Br J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacol Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e126219","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti\u2013siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/all.16004","article-title":"Regulation of mast cells by overlapping but distinct protein interactions of Siglec-6 and Siglec-8","volume":"79","author":"Korver","year":"2024","journal-title":"Allergy"},{"key":"B53","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41565-023-01584-z","article-title":"Controlled adsorption of multiple bioactive proteins enables targeted mast cell nanotherapy","volume":"19","author":"Du","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1494025","article-title":"Single-cell transcriptomics reveals the heterogeneity and function of mast cells in human ccRCC","volume":"15","author":"Song","year":"2025","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e154191","DOI":"10.1172\/jci.insight.154191","article-title":"TET2 regulates immune tolerance in chronically activated mast cells","volume":"7","author":"Rigo","year":"2022","journal-title":"JCI Insight"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1477072","article-title":"Neuronal substance P-driven MRGPRX2-dependent mast cell degranulation products differentially promote vascular permeability","volume":"15","author":"Nagamine","year":"2024","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/JLB.3MA1219-210RR","article-title":"A humanized mouse model to study mast cells mediated cutaneous adverse drug reactions","volume":"107","author":"Mencarelli","year":"2020","journal-title":"J Leukocyte Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/ijms26030927","article-title":"Mast cells at the crossroads of hypersensitivity reactions and neurogenic inflammation","volume":"26","author":"Aitella","year":"2025","journal-title":"IJMS"},{"key":"B59","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jaci.2024.11.021","article-title":"MRGPRX2 facilitates IgE-mediated systemic anaphylaxis in a newly established knock-in mouse model","volume":"155","author":"Bawazir","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.3390\/ijms24065275","article-title":"KIT D816V mast cells derived from induced pluripotent stem cells recapitulate systemic mastocytosis transcriptional profile","volume":"24","author":"De Toledo","year":"2023","journal-title":"IJMS"},{"key":"B61","doi-asserted-by":"publisher","first-page":"10014","DOI":"10.1038\/s41598-025-94841-1","article-title":"Serum MRGPRX2 and substance P levels are biomarkers of disease activity rather than an antihistamine response in chronic spontaneous urticaria","volume":"15","author":"Cuc","year":"2025","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/cea.14531","article-title":"Mas-related G-protein coupled receptor- X2 and chemokine (C\u2013C motif) ligand 2 correlate with disease activity among treatment-na\u00efve chinese patients with chronic spontaneous urticaria","volume":"55","author":"Lao","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/cea.70068","article-title":"Variants of the MRGPRX2 gene found in patients with hypersensitivity to quinolones and vancomycin show amplified and drug-specific activation responses in vitro","volume":"55","author":"Quan","year":"2025","journal-title":"Clin Exp Allergy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680574\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:15:10Z","timestamp":1760415310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680574\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1680574"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1680574","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"article-number":"1680574"}}